Natus Medical (BABY) Releases FY13 Earnings Guidance
Natus Medical (BABY) issued an update on its FY13 earnings guidance on Monday morning. The company provided earnings per share guidance of $0.81-0.84 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.82. The company issued revenue guidance of $362-367 million, compared to the consensus revenue estimate of $346.66 million.Natus Medical also updated its Q1 guidance to $0.09-0.10 EPS.
Natus Medical (BABY) opened at 11.90 on Monday. Natus Medical (BABY) has a 52-week low of $9.61 and a 52-week high of $13.84. The stock’s 50-day moving average is currently $11.03. The company’s market cap is $347.3 million.
Natus Medical last posted its quarterly earnings results on Wednesday, November 7th. The company reported $0.15 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.14 by $0.01. The company had revenue of $80.70 million for the quarter, compared to the consensus estimate of $81.37 million. During the same quarter in 2012, the company posted $0.07 earnings per share. The company’s revenue for the quarter was up 57.3% on a year-over-year basis. Natus Medical has set its Q4 guidance at $0.25-0.28 EPS and its FY12 guidance at $0.58-0.61 EPS. On average, analysts predict that Natus Medical (BABY) will post $0.60 earnings per share for the current fiscal year.
Natus Medical Incorporated (Natus) is a provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and balance and mobility disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.